ANZCTR search results

The QH Rural Stroke Outreach Service and the Queensland Rehabilitation Physiotherapy Network are investigating the use of the Bioness NESS L300 (L300) to support gait recovery in people following stroke with foot drop. A prospective clinical controlled study involving eight rehabilitation units is planned. Each participating site has nominated to be either an intervention or a control site. Following familiarisation, participants will use the L300 during physiotherapy treatment once medically stable until they are discharged or the L300 is no longer clinically required. Participants will be followed up by phone at 4, 8 and 12 weeks following recruitment to the study.

An Open-label, Single-Dose, 3-Period Crossover Study To Evaluate the 2-Way Interaction of Sitagliptin and Losartan in Healthy Adult Subjects MK0431G (combination treatment) is being developed for treatment of patients for whom treatment with both Sitagliptin and Losartan is appropriate. However, this study is in healthy volunteers only.

It is well known that pain management in emergency departments (EDs) could often be improved. A recent study demonstrated that the provision of 'adequate analgesia' (defined as a reduction in the patient's triage pain score of at least 2 and to a level <4 [0-10 scale]) is significantly associated with a high level of patient satisfaction with their pain management. The study concluded that this definition of 'adequate analgesia' could be used as a clinical target for ED staff to aim for. However, this study was only able to demonstrate an association between the provision of 'adequate analgesia' and patient satisfaction. Despite this, the strength of the association is very strong and the 'adequate analgesia' target is about to be rolled out into ED clinical practice. The proposed study aims to take advantage of this proposed roll out by determining if the use of the 'adequate analgesia' target (the intervention) will result in improved patient satisfaction.

This study aims to compare the outcome of early tube feeding compared to commencement of feeding as per current standard practice in patients undergoing gastrostomy prior to treatment for head and neck cancer. Who is it for? You may be eligible to join this study if you are aged 18 years or above, have been diagnosed with head and neck cancer, and have been referred for a preventive gastrostomy (insertion of feeding tube into the stomach) prior to treatment for your cancer. Trial details Participants in this trial will be randomly (by chance) allocated to one of two treatment groups. Participants in one group will commence two supplementary feeds per day at the time of feeding tube insertion (gastrostomy). These feeds will be in addition to the patient's usual dietary intake and will continue throughout cancer treatment. Participants in the other group will receive standard care. This involves water flushes via the gastrostomy throughout cancer treatment and feeds will be commenced by the dietitian as clinically indicated during treatment. Participants will be assessed at baseline and 3 months post completion of treatment in order to determine impact on nutrition outcomes, quality of life and clinical outcomes.

The PEP study is a partnership between New South Wales, Flinders, Monash, Bond and Queensland Universities, the Royal Australian College of General Practitioners (RACGP), the National Heart Foundation of Australia (NHFA) and the BUPA Foundation. The study is in response to the need to evaluate the uptake and effectiveness of current guidelines for the prevention of chronic disease in general practice, and to develop innovative and effective implementation strategies for the future. The aims of this partnership are to design, trial and evaluate a framework to improve the implementation of the RACGP, the NHFA and NHMRC guidelines for prevention of chronic disease in general practice.

The purpose of this study is to assess the impact of personalised mobile telephone short messages (SMS) on improving skin protection and early skin cancer detection behaviours among young to mid-aged adults (18 to 42 years). Who is it for? This study is open to consenting participants aged 18-42 years, understand sufficient English, own a private mobile phone, and who have had no previous melanoma with Fitzpatrick skin types I-III (skin that always, usually or sometimes burns and never or sometimes tans). Trial details Participants in this study will be randomised into one of two groups, where both groups will receive a total of 21 personalised text messages over a period of 12 months relating to either sun safety or skin self examination OR in relation to physical activity. The frequency of these text messages is as follows: One message per week for the first three months of the study, then one message per month for the remaining nine months. There are two primary hypotheses for this trial: 1) Provision of personalised sun protection SMS will reduce the proportion of intervention group participants reporting two or more sunburns during the past twelve months by at least 15% compared to no change in the attention control group (physical activity SMS). 2) Provision of personalised skin cancer early detection SMS will increase the proportion of intervention participants who report a whole-body skin self-examination in the past twelve months by at least 10% compared to no change in the attention control group (physical activity SMS). We will also measure satisfaction with, use of, and recall of the SMS messages. The associated secondary hypothesis is that SMS messages are an acceptable and feasible method of reaching people aged 18-42 years with personalised skin cancer prevention messages.

The purpose of the study is to find out if the drug "Vessel Dilator" (VSDL) is absorbed from an infusion under the skin and whether it improves heart function and has an effect on kidney function in people diagnosed with stable congestive heart failure and a moderate degree of kidney function loss

Allogeneic haemopoietic stem cell transplantation (HSCT) is a potentially curative procedure for a wide range of haematological malignancies, but the benefit of the graft versus malignancy effect is often offset by increased toxicity of graft versus host disease (GVHD) and infection. Reduced intensity conditioning (RIC) regimens have become more commonly used over the last 10 years in HSCT in an attempt to provide the potential curative benefit of allografting to a wider patient population. Most published literature on RIC transplantation has concentrated on one disease and the relative benefit of a particular form of RIC conditioning in that disease setting. There have been few studies analyzing a commonly used regimen and assessing its benefit across several disease groups. Indeed, there is no consensus on the relative benefits of a certain RIC regimen even in myeloid or lymphoid malignancies as a general group of diseases. In this study, we retrospectively assess the relative benefits of FluMel RIC HSCT from 1998-2008, in a large cohort of patients with either lymphoid or myeloid malignancies.

To review the effects of utilising reverse taper Peripherally Inserted Central Catheters (PICCs), specifically in relation to thrombus formation in deep upper limb vessels.

This randomised clinical trial is investigating the preventive effect of subcutaneous methylnaltrexone, in comparison with placebo, on the severity of pruritus in women receiving spinal anaesthesia including intrathecal morphine for caesarean section.